The Second Affiliated Hosp of Xi'an Jiaotong Univ College of Medicine ( Site 0831) Trials

The Second Affiliated Hosp of Xi'an Jiaotong Univ College of Medicine ( Site 0831)	Welcome, Profile Billing Logout

The Second Affiliated Hosp of Xi'an Jiaotong Univ College of Medicine ( Site 0831)

Welcome, Profile Billing Logout

1 Trial

1 Trials

Active Trials Industry lead sponsorIndustry collaborator

Export

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Chong, Tie

NCT04691804 / 2020-006063-28: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer

Active, not recruiting

496

Europe, US, RoW

Fuzuloparib , Abiraterone acetate and Prednisone, SHR3162, Fuzuloparib Placebo， Abiraterone acetate and Prednisone

Jiangsu HengRui Medicine Co., Ltd.

Metastatic Castration-Resistant Prostate Cancer (mCRPC)

12/26

Download Options



	Diseases Companies Products Productz Mechanisms of Action Sites